Last $1.39 USD
Change Today +0.01 / 0.72%
Volume 138.8K
As of 5:20 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

curis inc (CRIS) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/22/13 - $4.59
52 Week Low
10/10/14 - $1.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CURIS INC (CRIS)

curis inc (CRIS) Related Businessweek News

No Related Businessweek News Found

curis inc (CRIS) Details

Curis, Inc. is engaged in the research, development, and commercialization of cancer therapeutics. It focuses on developing cancer drug candidates, including CUDC-907, an oral, small molecule drug candidate that is designed to inhibit histone deacetylase and phosphatidylinositol-3-kinase, or PI3K enzymes; CUDC-427, an oral, small molecule drug candidate, which is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins; Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor; and Debio 0932, a small molecule inhibitor of heat shock protein 90. It has collaborations with Genentech, Inc. and F. Hoffmann-La Roche Ltd. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

33 Employees
Last Reported Date: 03/13/14
Founded in 2000

curis inc (CRIS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $366.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $360.0K
Vice Chairman and Strategic Advisor
Total Annual Compensation: $464.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $142.8K
Vice President of Technology Management & Int...
Total Annual Compensation: $230.0K
Compensation as of Fiscal Year 2013.

curis inc (CRIS) Key Developments

Curis, Inc. Announces CUDC-907 Trails Advancements

Curis, Inc. announced advances in the development of CUDC-907, its oral, dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes that is currently under investigation in a first-in-human single agent trial in patients with relapsed/refractory lymphomas or multiple myeloma. Curis has opened expansion cohorts in this ongoing Phase 1 study at the dose of 120 mg administered three times per week (TIW), which was determined to be the maximum tolerated (MTD) dose for this schedule in the dose escalation phase of the trial. The expansion phase of the trial is projected to enroll up to 12 patients each with either relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL) or multiple myeloma. The selection of DLBCL and multiple myeloma as lead hematologic indications for further investigation is supported by preclinical data as well as preliminary anti-cancer activity observed in the dose escalation phase of the ongoing trial. In addition, Curis announced that a second Investigational New Drug (IND) application for CUDC-907 has been accepted by the U.S. Food & Drug Administration and a new study will be initiated under this IND that will enroll patients with advanced solid tumors, including patients with hormone receptor positive breast cancer, among others.

Curis, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

Curis, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

Curis, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 08:00 AM

Curis, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 08:00 AM. Venue: The Palace Hotel, San Francisco, CA 94105, United States. Speakers: Ali Fattaey, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRIS:US $1.39 USD +0.01

CRIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.15 USD -0.04
Cytokinetics Inc $3.41 USD -0.06
Delcath Systems Inc $1.75 USD -0.01
MELA Sciences Inc $2.15 USD +0.30
Navidea Biopharmaceuticals Inc $1.46 USD +0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation CRIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.1x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CURIS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at